论文部分内容阅读
目的:探讨长链非编码RNA(lncRNA)LINC01358在前列腺癌组织中的表达及对前列腺癌细胞增殖和迁移的影响。方法:选取3对前列腺癌和癌旁组织,进行lncRNA芯片检测。利用MSKCC前列腺癌患者芯片数据库,比较LINC01358在前列腺癌癌旁、原发性前列腺癌组织和转移性前列腺癌组织中的表达。利用实时荧光定量PCR技术检测10对前列腺癌和癌旁组织中LINC01358的表达验证大数据的结果。采用干扰RNA降低前列腺癌细胞株DU145中LINC01358的表达,MTT检测DU145细胞的增殖,Transwell小室法测定细胞迁移。结果:在lncRNA芯片中,共有差异表达的lncRNA 79个,其中在肿瘤组织中高表达的有36个,在肿瘤组织中低表达的有43个,LINC01358在前列腺癌组织中高表达。MSKCC前列腺癌患者芯片数据库中,LINC01358在转移性前列腺癌组织(5.81±0.19,n=19)和原发性前列腺癌组织(5.47±0.04,n=131)中的表达高于癌旁组织(5.15±0.07,n=29),且与前列腺癌患者术后生化复发率相关(log-rank P<0.05)。实时荧光定量PCR验证大数据的结果提示,LINC01358在前列腺癌组织(6.02±1.12)中的表达明显高于癌旁组织(3.21±0.21,P<0.05)。应用干扰RNA转染DU145细胞后,LINC01358的表达明显下降。并且转染干扰RNA组和对照组相比,前列腺癌细胞增殖能力和迁移能力明显下降。结论:LINC01358在前列腺癌患者组织中高表达,敲低LINC01358表达可抑制前列腺癌细胞的增殖和迁移。LINC01358可能作为癌基因参与前列腺癌的发生发展,有望成为前列腺癌早期诊断指标及基因治疗的新靶点。
Objective: To investigate the expression of long chain non-coding RNA (LINC) 01358 in prostate cancer and its effect on the proliferation and migration of prostate cancer cells. Methods: Three pairs of prostate cancer and paracancerous tissues were selected for lncRNA microarray detection. Using the MSKCC Prostate Cancer Patient Database, the expression of LINC01358 in paracancer, paracancerous and metastatic prostate cancer tissues was compared. Real-time fluorescence quantitative PCR was used to detect the expression of LINC01358 in 10 pairs of prostate cancer and paracancerous tissue to verify the result of big data. Interference RNA was used to reduce the expression of LINC01358 in prostate cancer cell line DU145. The proliferation of DU145 cells was detected by MTT assay and the cell migration was measured by Transwell chamber assay. RESULTS: There were 79 lncRNAs differentially expressed in lncRNAs, of which 36 were highly expressed in tumor tissues, 43 were low in tumor tissues, and LINC01358 was overexpressed in prostate cancer tissues. The expression of LINC01358 in metastatic prostate cancer (5.81 ± 0.19, n = 19) and primary prostate cancer (5.47 ± 0.04, n = 131) was higher in the MSKCC prostate cancer patient database than in the adjacent tissues ± 0.07, n = 29), and was associated with postoperative biochemical recurrence rate in patients with prostate cancer (log-rank P <0.05). Real-time quantitative PCR confirmed the results of large data suggest that LINC01358 in prostate cancer tissue (6.02 ± 1.12) was significantly higher than the expression of adjacent tissues (3.21 ± 0.21, P <0.05). After transfection of DU145 cells with interfering RNA, the expression of LINC01358 was significantly decreased. Compared with the control group, the proliferation and migration ability of prostate cancer cells were significantly decreased. Conclusion: LINC01358 is overexpressed in prostate cancer tissues. Knockdown of LINC01358 can inhibit the proliferation and migration of prostate cancer cells. LINC01358 may participate in the development of prostate cancer as an oncogene and is expected to become a new target of early diagnosis of prostate cancer and gene therapy.